Business & Economy · 6 views
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
Business & Economy 
Story intelligence
Coverage Single outlet Single-outlet story
Views 6 Community interest
Brief read Under 1 min brief 17 words
Summary
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- OpenAI CFO says blue tsunami ‘didn’t dramatically change’ IPO plansContinue reading
- OpenAI wants to win over data-center opponents by calling them ‘compute campuses’ and promising local benefitsContinue reading
- ‘We’re losing to cottage cheese’: The protein-maxxing craze is hurting cream cheese salesContinue reading
- Over a quarter of Gen Z say they’d choose their dream home over their dream job—and they’re moving back in with mom and dad to make it happenContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow